AT1 FY21 - General Discussion + FA, page-394

Posting this here as the other AccBio-AT1 Ag test thread is old now..

AT's partner, AccBio, continues to sell heaps of its Ag test (that we signed up for India/ANZ) - no doubt due to the current US infection control needs.

3 Dec'20 - KRX disclosure; AccBio US distro (Intrivo Diagnostics) ordered another US$12m worth Ag tests
_{http://dart.fss.or.kr/dsaf001/main.do?rcpNo=20201203900077}

To put this order in perspective,
- Nov'20, Intrivo Diagnostics ordered US$4.23m worth Ag tests
- Nov'20, their new partner Ginkgo Bioworks ordered 10m Ag tests (undisclosed $)
- Oct'20, Intrivo Diagnostics ordered US$4m worth Ag tests

(I believe) CY19 total revenue from all test sales was ~$36m. As of Q3 CY20, it had reached [email protected], so looks like on track to exceed annual rev by end Q4 CY20.

Here's hoping some of that Ag revenue ($ luck) rubs off on AT1 too in FY21-22.